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Abstract 
 
Previous studies have identified associations between dietary and lifestyle factors and 
the incidence, risk of recurrence, and mortality of colorectal cancer. The consumption of 
coffee is one such factor that has been positively associated with improved prognosis in 
colorectal cancer patients, a finding that has been supported by both epidemiological and 
laboratory-based in vivo and in vitro studies. Using data collected as part of a national phase 
III randomized clinical trial (CALGB/SWOG 80405), we conducted a prospective 
epidemiological study of the effects of coffee consumption on survival in metastatic 
colorectal cancer patients. To our knowledge, this is the first study to examine the prognostic 
impact of coffee consumption in patients with metastatic colorectal cancer. Among this cohort 
of patients, we detected a significant inverse association between the increasing consumption 
of coffee and a decreased hazard of both cancer progression and death from any cause. 
Participants who consumed 4 or more cups of coffee per day had an adjusted hazard ratio for 
overall mortality of 0.62 (95% CI, 0.43 to 0.89; Ptrend = 0.008) and an adjusted hazard ratio 
for disease progression or death of 0.71 (95% CI, 0.52 to 0.98; Ptrend = 0.04). These findings 
were consistent across strata of demographic, clinical, and disease characteristics, and a 
significant interaction was noted between coffee consumption and adherence to a healthy 
‘prudent’ dietary pattern (Pinteraction = 0.01). Our results suggest a role for coffee consumption 
in the prognosis of patients with colorectal cancer, possibly mediated by its anti-oxidant and 
anti-inflammatory properties, or effects on insulin-sensitizing pathways. Further research is 
warranted to fully characterize these possible underlying mechanisms.  
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Chapter I 
Introduction 
 Despite advances in both treatment and detection, colorectal cancer remains a 
common and deadly disease in the United States. A large proportion of affected patients are 
diagnosed with metastatic disease at the time of clinical presentation or will ultimately 
develop distant metastases (Kindler & Shulman, 2001). Among these metastatic patients, 
median survival remains at approximately two years from diagnosis, and fewer than 6% of 
patients will survive for more than five years (Edge, 2010). It is clear that more needs to be 
done to improve the prognosis for patients diagnosed with this disease.  
 A number of previous studies have linked dietary and other lifestyle factors to the 
incidence of colorectal cancer (Cross et al., 2010; Hartz et al., 2012) and the risk of cancer 
recurrence after surgical resection of stage I-III disease (Meyerhardt et al., 2007; Meyerhardt 
et al., 2012; Fuchs et al., 2014). For example, a recent study found a correlation between 
higher intake of caffeinated coffee and significantly reduced cancer recurrence and death in 
patients with stage III resected colon cancer (Guercio et al., 2015). Various factors associated 
with an unhealthy lifestyle, such as higher BMI or more frequent alcohol consumption, have 
been correlated with increased risk of colon cancer related death (Chong et al., 2015). Though 
the molecular mechanisms underlying these factors are still largely unknown, there are clearly 
links between patients’ lifestyles and the pathogenesis of this disease.   
Less is known about the effects of such lifestyle factors in patients with metastatic 
colorectal cancer, although it is a great area of interest among patients diagnosed with this 
disease and the oncologists caring for them. A recent prospective epidemiological study found 
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a positive correlation between metastatic colorectal cancer patients’ plasma 25-
hydroxyvitamin D levels prior to initiating first-line palliative chemotherapy and the duration 
of their progression free and overall survival (Ng et al., 2015). In vivo studies have found that 
a high fat ‘Western’ diet up-regulates the EGFR pathway (Dougherty et al., 2015), and other 
factors such as green tea, ginseng, and curcumin down-regulate the same pathway (Pabla, 
2015). Ginseng in particular was shown to suppress the growth of colon tumors in xenografts 
(Pabla, 2015). Each of these findings suggests a potential for dietary consumption and other 
lifestyle factors to modify oncogenic processes associated with the growth and spread of 
cancer and its associated mortality.  
Recently, the consumption of coffee has garnered increasing interest. As cited above, a 
prospective epidemiological study published in 2015 used dietary data collected as part of 
CALGB/Alliance study 89803 to examine the influence of coffee, non-herbal tea, and 
caffeine intake on cancer recurrence in patients with resected stage III colon cancer. The study 
found that higher coffee intake was associated with significantly reduced cancer recurrence 
and death in this patient population (Guercio et al., 2015). Additionally, a randomized study 
showed a decreased risk of hepatocellular carcinoma among hepatitis C patients who 
consumed 4 cups of coffee per day compared to a control group that abstained from coffee 
(Cardin et al., 2013), and an in vitro study showed anti-tumor cell activity associated with 
kahweol, a diterpene molecule found in coffee beans (Choi et al., 2015). These data suggest 
that coffee may have a potential anti-cancer effect, though to our knowledge the effect of 
coffee consumption in patients with metastatic colorectal cancer has not been studied.  
In light of these promising data, we conducted a prospective epidemiological study 
evaluating the influence of coffee and tea consumption on survival in patients with metastatic 
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colorectal cancer. Prospective data collected as part of a completed phase III randomized 
clinical trial, CALGB/SWOG 80405, was used to examine this question. We examined 
differences in progression free survival and overall survival in metastatic colorectal cancer 
patients according to their daily consumption of coffee and tea. Our hypothesis was that 
patients who consumed more coffee would demonstrate longer progression free survival and 
overall survival compared to those who consumed less coffee. We additionally evaluated this 
association in subgroups of metastatic colorectal cancer patients stratified by known 
prognostic clinical and disease characteristics.  
 
Definition of Terms 
“Adiponectin”: a protein hormone involved in glucose metabolism that is secreted by 
adipocytes (fat cells) 
 
“Alliance/CALGB”: a national NCI-funded cooperative research group that focuses on cancer 
treatment and clinical research  
 
“C-peptide”: a short amino acid chain that is part of the structure of proinsulin, the precursor 
molecule to insulin   
 
“EGF(R)”: Epidermal Growth Factor (Receptor); a ligand and membrane bound receptor 
involved in cell growth and frequently implicated in the proliferation of cancer cells  
 
“IGF-1”: Insulin-like Growth Factor 1, a hormone that is similar in structure to insulin and 
associated with growth in adults; previous studied have linked high IGF-1 levels to cancer 
risk and survival 
 
“Insulin”: a hormone associated with glucose metabolism; several related molecules have 
been associated with risk of colon cancer  
 
“In vivo”: refers to experiments conducted in animal models  
 
“In vitro”: refers to experiments conducted in cell cultures  
 
4 
 
“Overall Survival”: length of time that a patient survives after diagnosis with a disease; 
frequently used as a marker of cancer treatment efficacy  
 
“Progression Free Survival”: length of time that a patient’s cancer remains radiologically 
and/or clinically stable; frequently used as a marker of cancer treatment efficacy  
 
“Recurrence”: a return of detectable cancer after curative-intent surgery or other interventions  
 
“Xenograft”: in cancer research, refers to an animal model in which human cancer cells are 
grown in a lab animal, frequently an immunosuppressed mouse  
 
 
Background 
Colorectal Cancer 
Colorectal cancer is the third most common cancer and second most common cause of 
cancer related death in the United States (American Cancer Society, 2013). While early 
detection can lead to improved patient outcomes as a result of curative surgery, 15 to 25% of 
patients are diagnosed with metastatic disease and a large proportion will ultimately develop 
metastases (Kindler & Shulman, 2001). Once metastatic disease is found, the cancer is no 
longer considered curable and treatment instead focuses on palliation of symptoms and 
extension of life. Recently developed targeted therapies and novel chemotherapeutic agents 
have modestly improved survival in this population (Cleghorn, 2015; Cutsem et al., 2015). 
However, the median survival time remains at 2 years and fewer than 6% of patients survive 
for greater than 5 years (Edge, 2010). While there is ongoing research to develop innovative 
pharmaceutical treatments for this disease, lifestyle modification may have a significant 
impact on prognosis when used in combination with current modalities, and offers the 
potential for clinical benefit without the cost and toxicities associated with standard therapies.   
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Lifestyle Influences on Colorectal Cancer 
 A number of previous studies have demonstrated relationships between lifestyle 
factors and the risk of colon cancer incidence and recurrence. Specifically, body-mass index, 
physical activity level, alcohol and tobacco use, and the consumption of red meat have been 
associated with the risk of developing colorectal cancer and/or the risk of recurrent cancer 
after surgical intervention (Meyerhardt et al., 2007; Meyerhardt et al., 2012; Fuchs et al., 
2014; Cross et al., 2010; Hartz et al., 2012). In some cases these associations are quite 
dramatic. A study in 2014 found that patients with stage III colon cancer who consumed 2 or 
more servings of sugar-sweetened beverages per day nearly doubled their relative risk of 
cancer recurrence after surgical resection (Fuchs et al., 2014). Another study in stage III colon 
cancer patients found decreased risk of cancer recurrence and longer overall survival in 
patients who consumed a healthier ‘prudent’ diet compared to a higher fat ‘western’ diet. This 
effect was biologically compelling due to its dose dependent nature – extreme ends of the 
prudent vs. western spectrum were the most strongly correlated with changes in risk of 
recurrence and mortality (Mayerhardt et al., 2007). Similarly, a positive correlation has been 
found between dietary glycemic load and colon cancer recurrence, and a negative correlation 
between weekly exercise hours and colon cancer recurrence (Meyerhardt et al., 2012; 
Michaud et al., 2001). An analysis of known cancer risk factors estimated that if all 40-year-
old males maintained a normal BMI, exercised for at least 15 hours per week, took a daily 
multivitamin, ate fewer than 3 servings of red meat per week, drank less than 1 serving of 
alcohol per day, and abstained from tobacco, 71% of colorectal cancer cases could be 
prevented (Platz et al., 2000). 
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 Other research has implicated specific foods and nutrition-related compounds in 
improvement of colorectal cancer outcome. 25-hydroxyvitamin D is an intriguing molecule 
which has been shown to reduce cancer growth and metastases in vivo and which may be a 
predictor of colorectal cancer survival in humans (Rossdeutscher et al., 2014; Ng et al., 2015). 
The wealth of data regarding the relationship between Vitamin D and colorectal cancer has 
led to several clinical trials investigating the effects of supplementing patients with high doses 
of vitamin D. Similarly, ginseng and curcumin have been shown to down-regulate the EGFR 
pathway in vivo and some data suggests the potential for these and other compounds to slow 
the growth of cancers in vivo (Pabla, 2015; Wargovich, 2001). Additionally, the consumption 
of nuts has been shown to decrease the risk of developing colorectal cancer (Yang et al., 
2015) as well as the risk of death from any cause (Bao et al., 2001). It is clear that a generally 
healthy lifestyle plays a role in decreased cancer risk and improved patient outcomes, and it 
may also be the case that consumption of specific compounds can alter these factors.  
  
Coffee Consumption and Cancer 
Coffee is one of the most commonly consumed beverages across the world and 
contains several antioxidants and other compounds that may play a role in cancer 
pathogenesis. Coffee is the largest source of dietary antioxidants in the United States (Bøhn et 
al., 2013), where 54% of adults reportedly consume coffee at least once per day (Harvard 
School of Public Health, 2015). Several lines of research suggest a relationship between 
coffee consumption and cancer, including colorectal cancer. A randomized study has shown a 
decreased risk of hepatocellular carcinoma among hepatitis C patients who consume coffee 
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(Cardin et al., 2013), and in vitro studies have shown anti-tumor cell activity associated with 
kahweol, a diterpene molecule found in coffee beans (Choi et al., 2015).  
Epidemiological evidence points toward protective effects of coffee consumption 
against the risk of developing colorectal cancer. A recent prospective epidemiological study 
examined the influence of coffee, tea, and caffeine consumption in 953 patients with resected 
stage III colon cancer. The study found a significantly reduced risk of cancer recurrence and 
cancer mortality in patients who consumed 4 or more cups of coffee per day as compared to 
those who abstained (HR, 0.48; 95% CI, 0.25 to 0.91; Ptrend = .002). Total caffeine intake was 
also associated with reduced risk of cancer recurrence and mortality (HR, 0.66; 95% CI, 0.47 
to 0.93; Ptrend = .006). These results remained consistent across other known predictors of 
cancer recurrence and mortality rates (Guercio et al., 2015).  
Other epidemiological studies have found similar effects. One study conducted within 
a Japanese population noted a decreased risk of colorectal adenomas in coffee drinkers versus 
abstainers (Budhathoki et al., 2015). A meta-analysis of coffee-related studies in colorectal 
cancer conducted in 2013 found a nonlinear relationship between intakes of greater than 4 
cups of coffee per day and reduced risk of colorectal cancer (Bøhn et al., 2013). Each of these 
previous studies examined the effects of coffee on primary colorectal cancer risk or cancer 
recurrence risk. To our knowledge, this is the first study to be conducted on the effects of 
coffee consumption in patients with metastatic disease.  
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Alliance/CALGB 80405 
Alliance for Clinical Trials in Oncology, formerly known as Cancer and Leukemia 
Group B, is an NCI-funded cooperative group that conducts clinical trials and research in 
several types of cancer, including colorectal cancer. The group recently completed a large, 
multi-center, randomized trial comparing two approved biological therapies (bevacizumab 
versus cetuximab) in combination with standard chemotherapy regimens (Irinotecan/5-
FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6), CALGB/SWOG 
80405. The primary objective of the trial was to determine which chemotherapy/antibody 
combination conferred longer survival. Ultimately the results demonstrated that both regimens 
are equivalent; no significant difference in survival was detected between the two arms 
(Venook et al., 2014).  
In addition to the demographics, treatment information, medical history, and disease 
information typically collected during the course of a clinical trial, participants in this study 
were asked to complete dietary and lifestyle questionnaires prior to initiating chemotherapy. 
The questionnaire asked patients to document their intake of greater than 100 food items 
(including coffee) as well as tobacco and alcohol use, over the counter drug use, physical 
activity, and other relevant behaviors. Previous research has demonstrated the validity of this 
questionnaire in large populations (see methods section) (Willett et al., 1985). Archival tumor 
samples were collected from all patients, and correlative research blood samples were drawn 
from patients prior to treatment initiation, 8 weeks after initiation, and at the time of disease 
progression or study termination. These biospecimens and surveys taken from a large cohort 
of metastatic colorectal cancer patients undergoing treatment with chemotherapy offer a 
unique opportunity to study lifestyle and molecular characteristics that may influence the 
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course of this disease. In light of the described research regarding coffee and the availability 
of this prospectively collected data, we conducted an epidemiological study within 
CALGB/SWOG 80405 examining the association of coffee intake with overall survival.  
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Chapter II 
Methods 
 
Study Participants 
Prospectively collected data from a cohort of participants enrolled in CALGB/SWOG 
80405 was analyzed in this study. The primary objective of the main clinical trial was to 
compare two approved metastatic colorectal cancer biologic therapies, cetuximab and 
bevacizumab, in combination with a standard chemotherapy backbone (Irinotecan/5-
FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) (investigator 
choice)). When the trial was originally initiated, participants could be randomized to 
cetuximab, bevacizumab, or both. Based on emerging clinical data, after 1420 patients had 
accrued the study was amended such that only KRAS wild type tumors were included and the 
combination cetuximab plus bevacizumab arm was deleted (Venook et al., 2014). Eligible 
patients were required to have had no previous treatment for metastatic disease, no known 
concurrent cancers, adequate blood counts and organ function, good performance status, and 
willingness to sign informed consent
 
(Venook et al., 2014). Patients were followed for both 
progression free survival and overall survival. Data collection and monitoring were conducted 
by the Alliance Statistics and Data Center. 
The results of the overall trial did not show a significant difference between 
cetuximab- vs. bevacizumab-based treatment, indicating that either combination is appropriate 
for the treatment of first line KRAS wild-type metastatic colorectal cancer (Venook et al., 
2014). Consequently, all patients were pooled for analysis of the primary objective. 
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Participants were excluded from our analysis if they did not complete a dietary questionnaire, 
left blank any of the questions related to coffee or tea, or reported significantly aberrant 
caloric intake (< 600 or > 4,200 calories/d for men; < 500 or > 3,500 calories/d for women). 
Participants were also excluded if they had cancer progression or death within 90 days of 
initiating treatment to avoid dietary assessment bias related to a decline in general health 
(Meyerhardt et al., 2012). After these exclusions, a total of 1160 patients were included in our 
analysis.  
 
 
 
 
 
Figure 1: Description of the study population. Of the 2334 patients enrolled in this study, 1357 
completed a lifestyle questionnaire. 113 of these were excluded due to cancer progression or 
death within 90 days of randomization, 57 were excluded due to significantly aberrant caloric 
intake (< 600 or > 4,200 calories/d for men; < 500 or > 3,500 calories/d for women), and 27 
were excluded due to leaving blank one or more questions about coffee or tea consumption. The 
remaining 1160 patients comprised the final study population for this analysis.  
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Dietary Assessment 
 The diet and lifestyle questionnaire used in this study has been validated by previous 
studies in large populations (Willett et al., 1985), and many cancer-related epidemiological 
studies have been published using data collected in this manner (Meyerhardt et al., 2007; 
Meyerhardt et al., 2012; Fuchs et al., 2014; Guercio et al., 2015). The questionnaire is based 
on semi-quantitative questions that ask participants to indicate the frequency with which they 
consume 131 food items and vitamin/mineral supplements. Participants indicate how often, on 
average, during the previous 3 months, they consumed a specific food portion size, ranging 
from 0 to 6 times per day. Among these food items are caffeinated coffee, decaffeinated 
coffee, and non-herbal tea (Willett et al., 1985).  Patients were divided into groups for 
analysis based on the numbers of cups of each beverage they reported per day.  
 
Statistical Analysis 
 As noted above, no significant differences were detected between the two cancer 
therapy arms in this study, allowing us to pool patients from both arms. As was done in the 
stage III colon cancer recurrence study (CALGB 89803), intake of total coffee, caffeinated 
coffee, and tea were stratified into five frequency categories (0, < 1, 1, 2 to 3, and ≥ 4 cups/d) 
(Guercio et al., 2015). Herbal teas may contain different compounds with varying levels of 
biological activity, and therefore only non-herbal tea was included in our analysis (National 
Cancer Institute, 2010). Due to the limited number of participants who reported consumption 
of greater than 2 cups of decaffeinated coffee per day, more limited frequency categories were 
used for this exposure in order to preserve statistical power (0, < 1, 1, and ≥ 2 cups/d). This is 
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consistent with the data analysis done in the stage III cancer recurrence study (Guercio et al., 
2015). 
 Cox proportional hazards regression was used to determine the effect of coffee and tea 
consumption on progression free survival and overall survival in our cohort of cancer patients 
(Cox, 1972). This type of analysis allowed us to control for other characteristics that can 
affect survival in colorectal cancer. We controlled for the following characteristics: total 
energy intake, sex, age, performance status, chemotherapy and biologic treatment arms, prior 
adjuvant chemotherapy, smoking history, alcohol consumption, body mass index, physical 
activity level, Western or prudent dietary pattern, glycemic load, sites of metastasis, and 
serum adiponectin level (a biomarker that was previously associated with coffee consumption 
and cancer progression) (Chong et al., 2015; Yamashita et al., 2012). All analyses were 
performed with SAS version 9.4 (SAS Institute, Cary, NC), and p values of .05 or less were 
considered statistically significant. 
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Chapter III 
Results 
 
Baseline Characteristics 
 Baseline characteristics by frequency of total coffee consumption are displayed in 
Table 1. Consistent with the findings from our analysis of coffee intake in stage III colon 
cancer patients, frequent coffee drinkers in this analysis were more likely to be white males. 
They were also more likely to be current or former smokers, had higher daily energy intake, 
and were more likely to follow a Western dietary pattern.  
 
Table 1: Baseline Characteristics and Total Coffee Consumption of Study Cohort 
 Coffee Intake (cups/day) 
Characteristics 0 cups/d <1 cups/d 1 cups/d 2-3 cups/d >4 cups/d 
Total coffee      
N 278 297 297 226 62 
Median (Range) 0.0 (0.0 - 0.0) 0.1 (0.0 - 0.5) 1.0 (0.5 - 1.4) 2.5 (1.6 - 3.3) 4.5 (3.5 - 12.0) 
Age (years)      
Median (Range) 54 (22 - 84) 58 (21 - 82) 63 (24 - 85) 62 (36 - 82) 59 (42 - 82) 
Gender, No. (%)      
Men 138 (49.6%) 176 (59.3%) 176 (59.3%) 140 (61.9%) 51 (82.3%) 
Women 140 (50.4%) 121 (40.7%) 121 (40.7%) 86 (38.1%) 11 (17.7%) 
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Table 1: Baseline Characteristics and Total Coffee Consumption of Study Cohort 
 Coffee Intake (cups/day) 
Characteristics 0 cups/d <1 cups/d 1 cups/d 2-3 cups/d >4 cups/d 
Race, No. (%)      
White 220 (79.1%) 234 (78.8%) 269 (90.6%) 214 (94.7%) 60 (96.8%) 
Black 35 (12.6%) 52 (17.5%) 18 (6.1%) 7 (3.1%) 2 (3.2%) 
Other 15 (5.4%) 8 (2.7%) 6 (2.0%) 3 (1.3%) 0 (0) 
Unknown 8 (2.9%) 3 (1.0%) 4 (1.3%) 2 (0.9%) 0 (0) 
Performance status,  
No. (%) 
     
ECOG 0 166 (59.7%) 179 (60.3%) 192 (64.6%) 144 (63.7%) 37 (59.7%) 
ECOG 1 112 (40.3%) 118 (39.7%) 105 (35.4%) 82 (36.3%) 25 (40.3%) 
Planned chemotherapy, 
No. (%) 
     
FOLFIRI 68 (24.5%) 54 (18.2%) 68 (22.9%) 51 (22.6%) 15 (24.2%) 
FOLFOX 210 (75.5%) 243 (81.8%) 229 (77.1%) 175 (77.4%) 47 (75.8%) 
Prior Adjuvant Chemo, 
No. (%) 
     
No 260 (93.5%) 271 (91.2%) 274 (92.3%) 205 (90.7%) 53 (85.5%) 
Yes 18 (6.5%) 26 (8.8%) 23 (7.7%) 21 (9.3%) 9 (14.5%) 
Assigned Treatment Arm, 
No. (%) 
     
Bevacizumab 101 (36.3%) 107 (36.0%) 120 (40.4%) 96 (42.5%) 24 (38.7%) 
Cetuximab 102 (36.7%) 123 (41.4%) 105 (35.4%) 66 (29.2%) 26 (41.9%) 
Bevacizumab + Cetuximab 75 (27.0%) 67 (22.6%) 72 (24.2%) 64 (28.3%) 12 (19.4%) 
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Table 1: Baseline Characteristics and Total Coffee Consumption of Study Cohort 
 Coffee Intake (cups/day) 
Characteristics 0 cups/d <1 cups/d 1 cups/d 2-3 cups/d >4 cups/d 
Liver Metastasis, No. (%)      
No 58 (20.9%) 55 (18.5%) 69 (23.2%) 61 (27.0%) 23 (37.1%) 
Yes 215 (77.3%) 234 (78.8%) 222 (74.7%) 162 (71.7%) 39 (62.9%) 
Unknown 5 (1.8%) 8 (2.7%) 6 (2.0%) 3 (1.3%) 0 (0) 
BMI (kg/m2)      
Median (Range) 27.9 (15.4 - 59.2) 27.3 (17.1 - 54.8) 27.2 (15.8 - 48.4) 27.2 (15.4 - 58.4) 27.4 (16.8 - 52.5) 
Physical activity  
(Met-hr/wk) 
     
Median (Range) 3.8 (0.0 - 280.3) 3.4 (0.0 - 123.0) 3.2 (0.0 - 112.7) 4.5 (0.0 - 131.6) 3.4 (0.0 - 112.9) 
Smoking, No. (%)      
Never 170 (61.2%) 149 (50.2%) 138 (46.5%) 55 (24.3%) 12 (19.4%) 
Current 13 (4.7%) 18 (6.1%) 28 (9.4%) 41 (18.1%) 19 (30.6%) 
Past 92 (33.1%) 128 (43.1%) 131 (44.1%) 129 (57.1%) 30 (48.4%) 
Missing 3 (1.1%) 2 (0.7%) 0 (0) 1 (0.4%) 1 (1.6%) 
Multivitamin use, No. (%)      
Never 83 (29.9%) 79 (26.6%) 83 (27.9%) 71 (31.4%) 24 (38.7%) 
Past 72 (25.9%) 84 (28.3%) 69 (23.2%) 56 (24.8%) 13 (21.0%) 
Current 117 (42.1%) 124 (41.8%) 127 (42.8%) 88 (38.9%) 25 (40.3%) 
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Table 1: Baseline Characteristics and Total Coffee Consumption of Study Cohort 
 Coffee Intake (cups/day) 
Characteristics 0 cups/d <1 cups/d 1 cups/d 2-3 cups/d >4 cups/d 
Missing 6 (2.2%) 10 (3.4%) 18 (6.1%) 11 (4.9%) 0 (0) 
 
Total energy consumed 
(kcal/day) 
     
Median (Range) 1706.6 (601.1 - 
4038.3) 
1714.3 (526.5 -
4012.4) 
1819.8 (559.7 - 
3945.8) 
1972.2 (669.3 - 
4087.8) 
2235.2 (791.5 - 
4121.6) 
Alcohol (grams/d), 
energy-adjusted 
     
Median (Range) 0.0 (0.0 - 90.8) 0.4 (0.0 - 95.4) 1.1 (0.0 - 86.8) 1.1 (0.0 - 137.1) 0.7 (0.0 - 29.3) 
Glycemic load, energy-
adjusted 
     
Median (Range) 149.5 (39.9 - 
249.9) 
142.1 (77.5 - 
245.9) 
142.2 (79.3 - 
217.5) 
133.8 (57.3 - 
212.7) 
136.2 (93.9 - 
192.7) 
Glycemic index, energy-
adjusted 
     
Median (Range) 56.3 (39.3 - 75.6) 54.9 (40.8 - 70.7) 54.8 (42.3 - 72.7) 53.9 (43.9 - 72.0) 54.3 (46.3 - 65.8) 
Western dietary pattern, 
No. (%) 
     
≥median 103 (37.1) 122 (41.1) 148 (49.8) 155 (68.6) 54 (87.1) 
Prudent dietary pattern, 
No. (%) 
     
≥median 122 (43.9) 142 (47.8) 160 (53.9) 123 (54.4) 27 (43.6) 
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Impact of Coffee Intake on Cancer Progression and Overall Survival 
 Increasing total coffee intake was associated with a significant decrease in the risk of 
both overall mortality and disease progression after adjusting for other variables that are 
associated with cancer prognosis. Participants who consumed 4 or more cups of coffee per 
day had an adjusted hazard ratio for mortality of 0.62 (95% CI, 0.43 to 0.89; Ptrend = 0.008) 
compared to patients who did not drink coffee. They also had an adjusted hazard ratio for 
disease progression of 0.71 (95% CI, 0.52 to 0.98; Ptrend = 0.04).  
 Improved outcomes were also found when caffeinated coffee and decaffeinated coffee 
were individually analyzed. Compared to abstainers, those who consumed 4 or more cups of 
caffeinated coffee per day had an adjusted hazard ratio for mortality of 0.67 (95% CI, 0.45 to 
0.99; Ptrend = 0.05) and for disease progression of 0.76 (95% CI, 0.54 to 1.07; Ptrend = 0.03). 
Similarly, those who consumed 4 or more cups of decaffeinated coffee per day had an 
adjusted hazard ratio for mortality of 0.64 (95% CI, 0.41 to 0.98; Ptrend = 0.009). 
Consumption of decaffeinated coffee was not found to be significantly associated with 
progression-free survival. Consumption of non-herbal tea was not associated with any change 
in patient outcomes.  
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Abbreviations: PFS, progression free survival; OS overall survival; HR, hazard ratio 
ǂ Two Sided P Value; Trend across consumption levels  
* Adjusted for participants’ energy intake (kcal/d, continuous)   
** Adjusted for total energy intake (kcal/d, continuous), sex, age (years, continuous), 
performance status (0,1,2), planned chemotherapy (FOLFIRI, FOLFOX), prior adjuvant 
chemotherapy (yes, no), assigned treatment arm (bevacizumab, cetuximab, both),  
smoking history (never, past, current, missing), alcohol consumption (continuous, 
grams/d), body mass index (continuous, kg/m2), physical activity level (continuous, or 
missing), Western dietary pattern (continuous), prudent dietary pattern (continuous),  
glycemic load (continuous), liver metastasis (yes, no, or missing) 
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Figure 2: (A) Overall survival according to consumption of total coffee. (B) Progression-
free survival according to consumption of total coffee. 
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Stratified Analysis 
 We additionally analyzed the influence of total coffee consumption on overall survival 
and progression free survival across strata of other potential predictors of patient outcome. 
The trend of decreased risk of death or disease progression with increasing coffee 
consumption appeared to remain consistent across strata of most patient, disease, and 
treatment variables (Tables 3 and 4, respectively). The association between decreased risk of 
disease progression and increased coffee consumption was found to be stronger in patients 
who were more adherent to a prudent dietary pattern (Pinteraction = 0.03). No other significant 
interactions were detected.  
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Pinteraction = two-sided P value; trend across consumption levels  
Multivariable model adjusted for age, gender, performance status (0,1), planned chemotherapy (FOLFIRI, 
FOLOFOX), prior adjuvant chemotherapy (yes, no), assigned treatment arm (bevacizumab, cetuximab, 
both), BMI (continuous), physical activity (continuous, missing as a dummy variable), race (White, Black, 
Other, Unknown), season (Winter, Spring, Summer, Fall, Missing), region (Canada: Northeast, 
Midwest/west; United States: Northeast, Midwest/west, South) and RAS mutation status (wild-type, 
mutant, unknown)  
 
Pinteraction = two-sided P value; trend across consumption levels  
Adjusting with Cox proportional hazards regression for age, gender, performance status (0,1,2), 
planned chemotherapy (FOLFIRI, FOLOFOX), prior adjuvant chemotherapy (yes, no), assigned 
treatment arm (bevacizumab, cetuximab, both), BMI (continuous), physical activity (continuous, 
missing as a dummy variable), race (White, Black, Other, Unknown), season (Winter, Spring, 
Summer, Fall, Missing), region (Canada: northeast, Midwest/west; United States: Northeast, 
Midwest/west, South) and RAS mutation status (wild-type, mutant, unknown)  
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Chapter IV 
Discussion 
 
 The results from this prospective epidemiological study were consistent with our 
hypothesis: increased consumption of coffee was associated with a significant improvement in 
both progression free survival and overall survival in metastatic colorectal cancer patients. 
Unlike the previous study on cancer recurrence in patients who had been treated for stage III 
colon cancer, which found a benefit for caffeinated coffee only, this study found similar 
results for both caffeinated and decaffeinated coffee consumption. These associations were 
consistent across participant, disease, and treatment characteristics and remained significant 
after controlling for other factors known or suspected to affect survival in colorectal cancer 
patients. A significant interaction was detected between coffee consumption and patients’ 
adherence to prudent dietary patterns, two factors previously correlated with colorectal cancer 
development and outcomes (Hartz et al., 2012; Meyerhardt et al., 2007; Platz et al., 2000).  
 Previous studies, including the study that examined coffee consumption in stage III 
colon cancer, have proposed that coffee may act to reduce colorectal cancer recurrence 
through caffeine’s insulin sensitizing and anti-hyperinsulinemia effects. This hypothesis is 
primarily based on studies that have linked high energy states to cancer progression and 
mortality, and is supported by the finding in our previous study that only caffeinated coffee 
intake was significantly associated with decreased mortality (Meyerhardt et al., 2007; 
Meyerhardt et al., 2012; Fuchs et al., 2014; Guercio et al., 2015). Interestingly, the present 
study found a statistically significant decrease in mortality in both caffeinated coffee and 
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decaffeinated coffee drinkers, suggesting that caffeine may not be the only molecule 
conferring a protective effect. Although several studies have demonstrated an inverse 
relationship between caffeine itself and insulin levels, as well as between caffeine and the risk 
of type 2 diabetes, several prospective studies and meta-analyses have also shown a 
relationship between decaffeinated coffee and the insulin pathway (Keijzers et al., 2002; Ding 
et al., 2014). For example, another prospective study found a decrease in hemoglobin A1c, a 
marker of diabetes, associated with decaffeinated coffee (Zhang et al., 2009). It is therefore 
reasonable to conclude that both caffeine and other compounds found in coffee may play a 
role in its protective effect. One such candidate is chlorogenic acid, which has been shown to 
modify glucose levels and tolerance in humans and rats (Tunnicliffe et al., 2011; Johnston et 
al., 2003). 
 Besides its insulin-sensitizing effects, coffee may contain molecules that slow tumor 
growth via other mechanisms. Coffee is the largest source of dietary antioxidants in the 
United States (Bøhn et al., 2013). One such antioxidant, kahweol, has been shown to slow the 
growth of tumor cells in vitro, an effect that may be mediated by kahweol’s anti-inflammatory 
and anti-angiogenic effects (Choi et al., 2015; Cárdenas et al., 2011). Previous studies have 
implicated high oxidative stress in colorectal carcinoma development and metastases (Babbs, 
1990; Baltruskeviciene, 2016; Gackowski et al., 2002). As such, a greater consumption of 
antioxidants could reasonably be hypothesized to slow the development of such cancers. In 
support of this possibility, the current study detected a greater benefit of coffee consumption a 
prudent diet, which is comprised of foods that contain higher concentrations of antioxidants. 
Coffee consumption has also been associated with anti-inflammatory and pro-apoptotic 
effects that may decrease mutagenesis and cancer progression (Lopez-Garcia et al., 2006; 
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Bøhn et al., 2013). Further research is ongoing to identify the specific molecules found in 
coffee and their impact on cancer treatment and survival in human patients. 
These results remained statistically significant after controlling for gender, age, 
performance status, planned chemotherapy, prior adjuvant chemotherapy, assigned treatment 
arm, smoking history, alcohol consumption, total energy intake, body mass index, physical 
activity level, Western dietary pattern, prudent dietary pattern, glycemic load, and the 
presence of liver metastases. However, despite this adjustment, it remains possible that our 
results were confounded by factors that were not captured in the clinical trial or associated 
questionnaire, such as sleep habits, employment, or physical activity not related to dedicated 
exercise hours. Furthermore, most patients who consume coffee while being treated for cancer 
likely consumed coffee before cancer diagnosis, so we cannot discern whether the 
consumption of coffee acts directly on active tumors or whether coffee drinkers tend to 
develop less aggressive tumors. However, either of these possibilities would suggest a role for 
compounds found in coffee in colorectal cancer outcomes. Finally, it is possible that the 
population of cancer patients enrolled on Alliance 80405 is not representative of the general 
population of colorectal cancer patients. However, this clinical trial recruited patients from 
both academic and community hospitals across the United States, and similar randomized 
clinical trials are routinely used to determine the standards of care for treatment of colorectal 
and other forms of cancer.  
 In conclusion, this large prospective epidemiological study detected an association 
between improved colorectal cancer outcomes and the increased consumption of coffee. The 
effect was strongest in patients who drank ≥4 cups of coffee per day and in patients who 
closely adhered to a prudent dietary pattern. These findings confirm the relationship between 
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coffee consumption and colorectal cancer outcomes that has been described by previous 
epidemiological studies, though this is the first such study done in patients with active, 
metastatic colorectal cancer. Further research is needed to elucidate the specific mechanism 
driving these associations.  
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